Getagraph.com logo
S&P 500
(0.91%) 5 064.20 points
Dow Jones
(0.85%) 38 226 points
Nasdaq
(1.51%) 15 841 points
Oil
(0.08%) $79.06
Gas
(5.02%) $2.03
Gold
(0.10%) $2 313.40
Silver
(0.68%) $26.93
Platinum
(0.85%) $963.00
USD/EUR
(-0.09%) $0.932
USD/NOK
(-0.27%) $11.00
USD/GBP
(-0.06%) $0.798
USD/RUB
(-2.30%) $91.12

Realaus laiko atnaujinimai POINT Biopharma Global [PNT]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta26 gruod. 2023 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

0.16% $ 12.50

Live Chart Being Loaded With Signals

Commentary (26 gruod. 2023 @ 23:00):
Profile picture for POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors...

Stats
Šios dienos apimtis 3.29M
Vidutinė apimtis 3.85M
Rinkos kapitalizacija 1.33B
EPS $0 ( 2024-03-25 )
Kita pelno data ( $0 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 11.36
ATR14 $0.322 (2.58%)
Insider Trading
Date Person Action Amount type
2023-12-26 Goodman Jonathan R. Sell 41 872 Common Stock
2023-12-27 Goodman Jonathan R. Sell 35 872 Stock Option (Right to Buy)
2023-12-27 Goodman Jonathan R. Sell 25 000 Stock Option (Right to Buy)
2023-12-27 Goodman Jonathan R. Sell 25 614 Stock Option (Right to Buy)
2023-12-27 Goodman Jonathan R. Sell 44 749 Stock Option (Right to Buy)
INSIDER POWER
-78.08
Last 96 transactions
Buy: 3 517 450 | Sell: 10 366 533

Tūris Koreliacija

Ilgas: 0.24 (neutral)
Trumpas: -0.64 (weak negative)
Signal:(35.382) Neutral

POINT Biopharma Global Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RCM0.813
LUNG0.806
TTWO0.805
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

POINT Biopharma Global Koreliacija - Valiuta/Žaliavos

The country flag 0.42
( neutral )
The country flag 0.44
( neutral )
The country flag 0.94
( very strong )
The country flag 0.73
( moderate )
The country flag 0.71
( moderate )
The country flag -0.62
( weak negative )

POINT Biopharma Global Finansinės ataskaitos

Annual 2022
Pajamos: $226.58M
Bruto pelnas: $226.58M (100.00 %)
EPS: $1.040
FY 2022
Pajamos: $226.58M
Bruto pelnas: $226.58M (100.00 %)
EPS: $1.040
FY 2021
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-1.181
FY 2020
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-0.00801

Financial Reports:

No articles found.

POINT Biopharma Global

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.